BIOLASE, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies - Additional Information (Detail)

Commitments and Contingencies - Additional Information (Detail)						1 Months Ended		12 Months Ended
	Dec. 10, 2021 ft²	Feb. 28, 2021 USD ($) shares	Feb. 04, 2020 ft²	Jan. 22, 2020 ft²	Jan. 25, 2019 USD ($) shares	Mar. 31, 2019 USD ($)	Jan. 31, 2019 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Commitment And Contingencies [Line Items]
Lease term			66 months	5 years
Operating lease, options to renew term								1 year
Lessee, Operating Lease, Existence of Option to Extend [true false]									true
Area of corporate headquarters and manufacturing facility \| ft²	15,000		12,000	11,000
Lease expiration date	Jun. 30, 2025		Jul. 01, 2020	Jul. 01, 2020				Dec. 31, 2025
Operating lease, right-of-use asset								$ 1,717,000	$ 1,976,000
Operating lease, liability								$ 1,854,000	2,079,000
Operating lease not yet commenced description								the only lease that had not commenced was for the additional facility lease in Corona, California
Payments for rent								$ 900,000	700,000	$ 800,000
Purchase commitments pending								18,700,000
Litigation settlement share issued \| shares		500,000
Contingent gain (loss) on patent litigation settlement								(315,000)
Accrued liability		$ 600,000						8,276,000	6,667,000
Settlement Agreement
Commitment And Contingencies [Line Items]
Accrued liability								800,000	1,000,000.0
Employee Arrangements and Other Compensation
Commitment And Contingencies [Line Items]
Change in control, if occurs, may require severance benefits payable								2,300,000	2,000,000.0
Accrued for performance bonuses								400,000	$ 800,000
Patent Litigation
Commitment And Contingencies [Line Items]
Contingent gain (loss) on patent litigation settlement						$ 200,000		$ 300,000
Patent Litigation \| Settlement Agreement
Commitment And Contingencies [Line Items]
Settlement agreement date					January 25, 2019
Number of days litigation settlement to be paid in cash					5 days
Litigation settlement in cash					$ 500,000
Number of days litigation settlement shares to be issued					30 days
Litigation settlement share issued \| shares					500,000
Number of days litigation settlement to be paid in value of stock consideration					30 days
Settlement agreement, terms								The Company agreed (i) to pay to CAO, within five days of the Effective Date, $500,000 in cash, (ii) to issue to CAO, within 30 days of the Effective Date, 500,000 restricted shares of BIOLASE common stock (the “Stock Consideration”), and (iii) to pay to CAO, within 30 days of December 31, 2021, an amount in cash equal to the difference (if positive) between $1,000,000 and the value of the Stock Consideration as of December 31, 2021.
Litigation settlement amount in cash equal to difference between value of stock consideration					$ 1,000,000
Contingent gain (loss) on patent litigation settlement											$ (1,500,000)
Payment for litigation settlement in cash							$ 500,000
Manufacturing Facility
Commitment And Contingencies [Line Items]
Lease expiration date								Jun. 30, 2025
Minimum
Commitment And Contingencies [Line Items]
Lease term								1 year
Maximum
Commitment And Contingencies [Line Items]
Lease term								5 years